 randomized comparison intravenous heparin oral aspirin dipyridamole hours recombinant tissue-type plasminogen activator acute myocardial infarction National Heart Foundation Australia Coronary Thrombolysis Group BACKGROUND study need heparin administration hours coronary thrombolysis recombinant tissue-type plasminogen activator rt-PA METHODS RESULTS total patients acute myocardial infarction mg rt-PA bolus units heparin units/hr i.v heparin hours hours patients intravenous heparin therapy full dosage heparin therapy oral antiplatelet regimen aspirin mg/day dipyridamole mg/day prospective recording differences pattern chest pain reinfarction complications Coronary angiography cardiac catheterization days differences patency infarct-related artery proportion patients total occlusion TIMI infarct-related artery heparin group aspirin dipyridamole group patients occluded infarct-related artery lumen normal heparin group aspirin dipyridamole group Left ventricular function cardiac catheterization radionuclide study day month differences groups Left ventricular ejection fraction radionuclide ventriculography month heparin group aspirin dipyridamole group CONCLUSIONS heparin therapy hours rt-PA therapy oral antiplatelet regimen adverse effects chest pain reinfarction coronary patency ventricular function